Prenatal and postnatal tobacco smoke exposure and respiratory health in Russian children

Abstract

Abstract Background Only few studies have assessed the relative impact of prenatal and postnatal exposure to tobacco smoke on the child's later asthma or chronic respiratory symptoms and to our knowledge no studies have elaborated respiratory infections and allergies in this context. Objective To assess the effects of prenatal and postnatal exposure to tobacco smoke on respiratory health of Russian school children. Methods We studied a population of 5951 children (8 to12 years old) from 9 Russian cities, whose parents answered a questionnaire on their children's respiratory health, home environment, and housing characteristics. The main health outcomes were asthma, allergies, chronic respiratory symptoms, chronic bronchitis, and upper respiratory infections. We used adjusted odds ratios (ORs) from logistic regression analyses as measures of effect. Results Prenatal exposure due to maternal smoking had the strongest effects on asthma (adjusted OR 2.46, 95% CI 1.19–5.08), chronic bronchitis (adjusted OR 1.45, 95% CI 1.08–1.96) and respiratory symptoms, such as wheezing (adjusted OR 1.30, 95% CI 0.90–1.89). The associations were weaker for exposure during early-life (adjusted ORs 1.38/1.27/1.15 respectively) and after 2 years of age (adjusted ORs 1.45/1.34/1.18) compared to prenatal exposure and the weakest or non-existent for current exposure (adjusted ORs 1.05/1.09/1.06). Upper respiratory infections were associated more strongly with early-life exposure (adjusted OR 1.25, 95% CI 1.09–1.42) than with prenatal (adjusted OR 0.74, 95% CI 0.54–1.01) or current exposure (adjusted OR1.05, 95% CI 0.92–1.20). The risk of allergies was also related to early life exposure to tobacco smoke (adjusted OR 1.26, 95% CI 1.13–1.42). Conclusion Adverse effects of tobacco smoke on asthma, chronic bronchitis, and chronic respiratory symptoms are strongest when smoking takes place during pregnancy. The relations are weaker for exposure during early-life and after 2 years of age and weakest or non-existent for current exposure.